Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation.

Yue Pan Yue Zeng Yurong Peng Xiaohan Liu Yizheng Li Fang Wu

Eur J Cancer

Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China; Human Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha, 410011, Hunan, China; Human Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China; Human Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. Electronic address:

Published: April 2022

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.ejca.2022.02.001	DOI Listing

Publication Analysis

Top Keywords

dramatic response

response brigatinib

brigatinib lung

lung adenocarcinoma

adenocarcinoma patient

patient harboring

harboring eml4-alk

eml4-alk fusion

fusion g1202r

g1202r novo

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!